COCP — Cocrystal Pharma Inc
NASDAQ · Healthcare · Biotechnology
$1.12
-$0.04 (-3.45%)
Cocrystal Pharma Inc (COCP) is a biotechnology company listed on NASDAQ. It is led by James R. Sapirstein M.B.A., R.Ph., based in 19805 North Creek Parkway, Bothell, WA, United States, 98011, with about 10 employees. Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases in the United States. The company employs structure-based technologies to create antiviral drugs including influenza virus, norovirus, coronaviruses, such as SARS-CoV-2 and MERS-CoV, as well as respiratory virus infections, and hepatitis C virus (HCV) infections. The company develops CC-42344, a novel PB2 inhibitor, which is in phase 2a clinical trial, as a potential treatment for pandemic and seasonal influenza A; and the inhaled CC-42344 for the potential prophylactic treatment of pandemic and seasonal influenza infections. It is also developing CDI-988, an oral pan-viral, which is a phase 1 clinical trial to treat noroviruses and coronaviruses, including SARS-CoV-2 and its variants; and CC-31244, an HCV non-nucleoside inhibitor that has completed Phase 2a clinical trial to treat HCV. The company has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. Cocrystal Pharma, Inc. was headquartered in Bothell, Washington.
Net income was -$2.0M. COCP currently screens at market cap $13.3M.
Use this COCP page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the COCP quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the COCP SEC filings page. Lician reads the product cache first so this HTML stays unique to Cocrystal Pharma Inc even when a live quote feed is slow.
About Cocrystal Pharma Inc
Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases in the United States. The company employs structure-based technologies to create antiviral drugs including influenza virus, norovirus, coronaviruses, such as SARS-CoV-2 and MERS-CoV, as well as respiratory virus infections, and hepatitis C virus (HCV) infections. The company develops CC-42344, a novel PB2 inhibitor, which is in phase 2a clinical trial, as a potential treatment for pandemic and seasonal influenza A; and the inhaled CC-42344 for the potential prophylactic treatment of pandemic and seasonal influenza infections. It is also developing CDI-988, an oral pan-viral, which is a phase 1 clinical trial to treat noroviruses and coronaviruses, including SARS-CoV-2 and its variants; and CC-31244, an HCV non-nucleoside inhibitor that has completed Phase 2a clinical trial to treat HCV. The company has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. Cocrystal Pharma, Inc. was headquartered in Bothell, Washington.
COCP Key Statistics
Market Cap
$13.30M
Volume
4,903
Previous Close
$1.11
Day Range
$1.10 – $1.12
EPS
-$1.72
Revenue
$0.00
Net Income
-$17.50M
Gross Profit
$0.00
Free Cash Flow
$0.00
Employees
10
COCP Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$17.50M | -$17.98M | -$38.84M | -$14.19M |
| EPS (Diluted) | -$1.72 | -$1.87 | -$4.77 | $0.00 |
Total Assets
$13.46M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$9.86M
Operating Cash Flow
-$16.48M
Free Cash Flow
$0.00
Cocrystal Pharma Inc Company Information
- Chief Executive Officer
- James R. Sapirstein M.B.A., R.Ph.
- Headquarters
- 19805 North Creek Parkway, Bothell, WA, United States, 98011
- Website
- www.cocrystalpharma.com
- Phone
- 877 262 7123
- IPO / Founded
- 2011-05-19
- Sector
- Healthcare
- Industry
- Biotechnology